文档介绍：HIGHLIGHTS OF PRESCRIBING INFORMATION • Metabolic Changes: Atypical antipsychotic drugs have been associated
These highlights do not include all the information needed to use with metabolic changes that may increase cardiovascular/
FANAPT safely and effectively. See full prescribing information for cerebrovascular risk. These metabolic changes include hyperglycemia,
FANAPT. dyslipidemia, and weight gain. ()
FANAPT® (iloperidone) tablets o Hyperglycemia and diabetes mellitus: Monitor patients for
Initial . Approval: 2009 symptoms of hyperglycemia including polydipsia, polyuria,
polyphagia, and weakness. Monitor glucose regularly in
WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS patients at risk for diabetes. ()
WITH DEMENTIA-RELATED PSYCHOSIS o Dyslipidemia: Undesirable alterations have been observed in
See full prescribing information for complete boxed warning. patients treated with atypical antipsychotics. ()
o Weight Gain: Weight gain has been reported. Monitor weight.
Elderly patients with dementia-related psychosis treated with ()
antipsychotic drugs are at an increased risk of death. FANAPT is not • Seizures: Use cautiously in patients with a history of seizures or with
approved for use in patients with dementia-relate